Is eFFECTOR Therapeutics, Inc. (EFTR) a Buy, Sell, or Hold?
OTC : EFTR
eFFECTOR Therapeutics, Inc.
$0.0002 USD
$0 (0.0%)
- Volume
- 331
- Average Volume
- 1.67K
- Market Capitalization
- $941
- P/E Ratio
- 0.00
- Dividend Yield
- 0.00%
- Price Target
- $5.50
- Year High
- $0.01
- Year Low
- $0.00
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $0.77
Company Overview
OTC
Craig R. Jalbert
Biotechnology
Healthcare
EFTR
14
US
USD
Liquidity Metrics
-3.55
0.77
0.77
0.58
0.00
Sales & Valuation
-$
0.00
0.00
0.00
-13.56
Profitability
-$16.37
-$35.81M
0.00%
0.00%
3771.56%
-174.31%
P/E Metrics
0.00
0.00
0.00
Analyst Price Target & Rating
$5.50
$10.00
$1.00
0/5
6 Analysts
-100.00%
Financial Health Scores
-13.56
2/9
$681K
$27.13M
$26.3M
-$31.95M
Key Metrics (TTM)
$5.67M
0.00
-0.17
0.77
3771.56%
-221.30%
-8187415.01%
-3150584.48%
-7662 days
Company Executives
| Name | Title |
|---|---|
| Kevan Shokat | Co-Founder and Member of Clinical & Scientific Advisory Board |
| Davide Ruggero | Co-Founder and Member of Clinical & Scientific Advisory Board |
Poll Results
No votes yet today — be the first to share your view!
About eFFECTOR Therapeutics, Inc. (OTC:EFTR) Stock
eFFECTOR Therapeutics, Inc. is a biopharmaceutical company in the clinical development stage, focused on devising innovative selective translation regulator inhibitors to treat various cancers. The company's primary investigational drug, Tomivosertib, is an orally administered small molecule that targets and inhibits MNK. This compound is currently undergoing a Phase 2b clinical study for patients diagnosed with metastatic non-small cell lung cancer. Furthermore, eFFECTOR is progressing with Zotatifin, another small-molecule therapeutic designed to block eukaryotic initiation factor 4A (eIF4E). Zotatifin is presently in Phase 2 clinical trials, exploring its efficacy in treating different solid tumors. A strategic alliance with Pfizer Inc. supports eFFECTOR's work on developing additional ... eIF4E inhibitors. Founded in 2012, eFFECTOR Therapeutics, Inc. maintains its operational base in Solana Beach, California.
Frequently Asked Questions
-
What is the current eFFECTOR Therapeutics, Inc. (EFTR) stock price?
-
eFFECTOR Therapeutics, Inc.(OTC:EFTR) stock price is $0.0002 in the last trading session. During the trading session, EFTR stock reached the peak price of $0.01 while $0.0002 was the lowest point it dropped to. The percentage change in EFTR stock occurred in the recent session was 0.0% while the dollar amount for the price change in EFTR stock was $0.
-
EFTR's industry and sector of operation?
-
The OTC listed EFTR is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of EFTR?
-
Kevan Shokat | Co-Founder and Member of Clinical & Scientific Advisory Board
Davide Ruggero | Co-Founder and Member of Clinical & Scientific Advisory Board
|
|
| -
How many employees does EFTR have?
-
Number of EFTR employees currently stands at 14. EFTR operates from 142 North Cedros Avenue, Solana Beach, CA 92075, US.
-
Link for EFTR official website?
-
Official Website of EFTR is: https://effector.com
-
How do I contact EFTR?
-
EFTR could be contacted at phone #858 925 8215 and can also be accessed through its website. EFTR operates from 142 North Cedros Avenue, Solana Beach, CA 92075, US.
-
How many shares of EFTR are traded daily?
-
The average number of EFTR shares traded daily for last 3 months was 1.67K.
-
What is the market cap of EFTR currently?
-
The market value of EFTR currently stands at $941 with its latest stock price at $0.0002